Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase III for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase III drugs for Chronic Lymphocytic Leukemia (CLL) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lisaftoclax’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lisaftoclax overview

Lisaftoclax (APG -2575) is under development for the treatment of B-cell cancers such as relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma, acute myeloid leukemia (AML), chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), diffuse large B-cell lymphoma, mantle cell lymphoma, chronic myelomonocytic leukemia, myelodysplastic syndrome, waldenstrom macroglobulinemia, T-cell prolymphocytic leukemia (r/r T-PLL), follicular lymphoma, hairy cell leukemia, solid tumors, acute lymphoblastic leukemia, metastatic ER positive, HER2 negative breast cancer and systemic lupus erythematosus (SLE). It is administered through oral route in the form of tablet. The drug candidate acts by targeting Bcl-2 protein.

Ascentage Pharma Group International overview

Ascentage Pharma Group International (Ascentage Pharma) is a biotechnology company that discovers and develops targeted small-molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It develops therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company product pipeline includes HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma lead candidate HQP8361 is a second-generation c-Met kinase inhibitor for the treatment of c-Met positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. It operates research and development centers and production facilities in Hong Kong, China, and the US. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.

For a complete picture of Lisaftoclax’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.